XPO7

Summary

XPO7 (exportin 7, HGNC:14108) is a protein-coding gene on chromosome 8p21.3, encoding Exportin-7 (Q9UIA9). Mediates the nuclear export of proteins (cargos) with broad substrate specificity.

The transport of protein and large RNAs through the nuclear pore complexes (NPC) is an energy-dependent and regulated process. The import of proteins with a nuclear localization signal (NLS) is accomplished by recognition of one or more clusters of basic amino acids by the importin-alpha/beta complex; see MIM 600685 and MIM 602738. The small GTPase RAN (MIM 601179) plays a key role in NLS-dependent protein import. RAN-binding protein-16 is a member of the importin-beta superfamily of nuclear transport receptors.

Source: NCBI Gene 23039 — RefSeq curated summary.

At a glance

• Gene–disease (curated): prostate cancer (Limited, GenCC)
• GWAS associations: 36
• Clinical variants (ClinVar): 95 total
• Druggable target: yes
• MANE Select transcript: NM_015024

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:14108
Approved symbol	XPO7
Name	exportin 7
Location	8p21.3
Locus type	gene with protein product
Status	Approved
Aliases	KIAA0745, EXP7
Ensembl gene	ENSG00000130227
Ensembl biotype	protein_coding
OMIM	606140
Entrez	23039

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 9 protein_coding, 3 retained_intron, 2 protein_coding_CDS_not_defined

ENST00000252512, ENST00000433566, ENST00000517551, ENST00000518017, ENST00000518808, ENST00000519769, ENST00000520754, ENST00000521303, ENST00000522015, ENST00000879830, ENST00000879831, ENST00000879832, ENST00000879833, ENST00000929054

RefSeq mRNA: 3 — MANE Select: NM_015024 NM_001100161, NM_001362802, NM_015024

CCDS: CCDS47818

Canonical transcript exons

ENST00000252512 — 28 exons

Exon	Start	End
ENSE00000893782	21995492	21995599
ENSE00000893785	21991868	21991974
ENSE00000893788	21990811	21990919
ENSE00000893790	21990344	21990407
ENSE00000893791	21989003	21989083
ENSE00000893793	21987784	21987857
ENSE00000893795	21987141	21987276
ENSE00000893797	21985586	21985691
ENSE00000893799	21984646	21984839
ENSE00000893801	21982640	21982812
ENSE00000893802	21981731	21981877
ENSE00000893803	21980084	21980203
ENSE00000893804	21977770	21977843
ENSE00000893805	21976356	21976521
ENSE00000980155	21998755	21998837
ENSE00000980156	21999091	21999305
ENSE00000980158	22002112	22002272
ENSE00000980159	22003219	22003317
ENSE00000980160	22003903	22004030
ENSE00001040999	21994363	21994451
ENSE00002102948	22004995	22006585
ENSE00002115088	21919662	21919788
ENSE00003504688	21970144	21970310
ENSE00003511886	21971876	21971941
ENSE00003559748	21969483	21969576
ENSE00003648723	21974670	21974774
ENSE00003662210	21966857	21967003
ENSE00003785387	21999536	21999674

Expression profiles

Bgee: expression breadth ubiquitous, 295 present calls, max score 97.48.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 26.5777 / max 1789.9734, expressed in 1811 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
87654	15.1774	1797
87655	9.1497	1732
87657	1.0998	63
87656	0.7264	68
87653	0.2469	86
87658	0.1776	24

Top tissues by expression

299 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
trabecular bone tissue	UBERON:0002483	97.48	gold quality
middle frontal gyrus	UBERON:0002702	95.70	gold quality
Brodmann (1909) area 10	UBERON:0013541	95.60	gold quality
frontal pole	UBERON:0002795	95.45	gold quality
bone marrow cell	CL:0002092	95.15	gold quality
paraflocculus	UBERON:0005351	95.08	gold quality
bone marrow	UBERON:0002371	94.88	gold quality
cortical plate	UBERON:0005343	94.78	gold quality
bone element	UBERON:0001474	94.15	gold quality
ventricular zone	UBERON:0003053	94.00	gold quality
ganglionic eminence	UBERON:0004023	93.85	gold quality
stromal cell of endometrium	CL:0002255	92.93	gold quality
islet of Langerhans	UBERON:0000006	92.82	gold quality
embryo	UBERON:0000922	92.75	gold quality
endometrium epithelium	UBERON:0004811	92.56	gold quality
left ovary	UBERON:0002119	91.67	gold quality
monocyte	CL:0000576	91.66	gold quality
mononuclear cell	CL:0000842	91.65	gold quality
prefrontal cortex	UBERON:0000451	91.58	gold quality
rectum	UBERON:0001052	91.58	gold quality
leukocyte	CL:0000738	91.55	gold quality
ectocervix	UBERON:0012249	91.52	gold quality
endocervix	UBERON:0000458	91.50	gold quality
right ovary	UBERON:0002118	91.36	gold quality
smooth muscle tissue	UBERON:0001135	91.26	gold quality
left lobe of thyroid gland	UBERON:0001120	91.19	gold quality
colonic epithelium	UBERON:0000397	91.18	gold quality
right lobe of thyroid gland	UBERON:0001119	91.05	gold quality
skin of leg	UBERON:0001511	90.90	gold quality
cerebellar cortex	UBERON:0002129	90.81	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.37

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

185 targeting XPO7, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-3925-3P	100.00	69.95	1237
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-MIR-3120-5P	100.00	65.56	965
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-485-3P	99.98	70.68	1585
HSA-MIR-539-3P	99.98	70.74	1616
HSA-MIR-4650-5P	99.98	64.69	999
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-3605-5P	99.96	67.12	932
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-381-3P	99.93	71.87	2854
HSA-MIR-497-5P	99.92	71.83	2674
HSA-MIR-300	99.92	71.76	2856
HSA-MIR-8063	99.91	69.76	3146
HSA-MIR-10527-5P	99.91	72.28	3754
HSA-MIR-15A-5P	99.90	72.80	2787

Literature-anchored findings (GeneRIF, showing 12)

• Exportin 7-dependent nuclear export signals differ fundamentally from the leucine-rich, CRM1-dependent ones (PMID:15282546)
• STRADalpha facilitates nuclear export of LKB1 by serving as an adaptor between LKB1 and exportins CRM1 and exportin7. (PMID:18256292)
• These biochemical and functional data reveal RANBP16 and RANBP17 as novel regulators of E2A protein action, and demonstrate specific interaction of E12 with RANBP17. (PMID:20503194)
• Knockdown of XPO7 reduced the amount of nuclear p65 following TNF stimulation. XPO7 binding to p65 is NLS independent (PMID:23906023)
• RAN nucleo-cytoplasmic transport and mitotic spindle assembly partners XPO7 and TPX2 have roles in serous epithelial ovarian cancer (PMID:24625450)
• Human oligodendrogliomas cells stably expressing mutant XPO7 showed altered cell proliferation. (PMID:25694352)
• Knockdown of exportins 4, 5, and 7 altered thyroid hormone receptor shuttling dynamics, and when exportins 5 and 7 were overexpressed, TR distribution shifted toward the cytosol. (PMID:25911113)
• This establishes Xpo7 as a broad-spectrum bidirectional transporter and paves the way for a much deeper analysis of exportin and importin function in the future. (PMID:29748336)
• XPO7 is a tumor suppressor regulating p21(CIP1)-dependent senescence. (PMID:33602872)
• CRISPR-based screening identifies XPO7 as a positive regulator of senescence. (PMID:36897256)
• Exportin XPO7 acts as an oncogenic factor in prostate cancer via upregulation of TCF3. (PMID:37000263)
• The GWAS SNP rs80207740 modulates erythrocyte traits via allele-specific binding of IKZF1 and targeting XPO7 gene. (PMID:38780091)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	xpo7	ENSDARG00000005540
mus_musculus	Xpo7	ENSMUSG00000022100
rattus_norvegicus	Xpo7	ENSRNOG00000013288
drosophila_melanogaster	Ranbp16	FBGN0053180
caenorhabditis_elegans		WBGENE00007952

Paralogs (2): XPO4 (ENSG00000132953), RANBP17 (ENSG00000204764)

Protein

Protein identifiers

Exportin-7 — Q9UIA9 (reviewed: Q9UIA9)

Alternative names: Ran-binding protein 16

All UniProt accessions (4): Q9UIA9, E5RIW1, E7ESC6, H0YBE1

UniProt curated annotations — full annotation on UniProt →

Function. Mediates the nuclear export of proteins (cargos) with broad substrate specificity. In the nucleus binds cooperatively to its cargo and to the GTPase Ran in its active GTP-bound form. Docking of this trimeric complex to the nuclear pore complex (NPC) is mediated through binding to nucleoporins. Upon transit of a nuclear export complex into the cytoplasm, disassembling of the complex and hydrolysis of Ran-GTP to Ran-GDP (induced by RANBP1 and RANGAP1, respectively) cause release of the cargo from the export receptor. XPO7 then return to the nuclear compartment and mediate another round of transport. The directionality of nuclear export is thought to be conferred by an asymmetric distribution of the GTP- and GDP-bound forms of Ran between the cytoplasm and nucleus.

Subunit / interactions. Binds to nucleoporins. Found in a complex with XPO7, EIF4A1, ARHGAP1, VPS26A, VPS29, VPS35 and SFN. Interacts with ARHGAP1 and SFN. Interacts with Ran and cargo proteins in a GTP-dependent manner.

Subcellular location. Cytoplasm. Nucleus.

Tissue specificity. Strong expression in testis, thyroid and bone marrow, low expression in lung, liver and small intestine, no expression in thymus, and remaining tissues studied have moderate expression. Expressed in red blood cells; overexpressed in red blood cells (cytoplasm) of patients with hereditary non-spherocytic hemolytic anemia of unknown etiology.

Similarity. Belongs to the exportin family.

RefSeq proteins (3): NP_001093631, NP_001349731, NP_055839* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001494	Importin-beta_N	Domain
IPR011989	ARM-like	Homologous_superfamily
IPR016024	ARM-type_fold	Homologous_superfamily
IPR044189	XPO4/7-like	Family
IPR057947	TPR_XPO7/RBP17	Domain

Pfam: PF03810, PF25795

UniProt features (8 total): modified residue 2, sequence variant 2, initiator methionine 1, chain 1, domain 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UIA9-F1	87.45	0.55

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 2, 570

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 270 (showing top): GSE45365_NK_CELL_VS_CD8_TCELL_DN, MORF_MTA1, RNGTGGGC_UNKNOWN, MORF_DNMT1, GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, GCANCTGNY_MYOD_Q6, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, MORF_HDAC1, MORF_CDK2, IVANOVA_HEMATOPOIESIS_MATURE_CELL, MORF_HDAC2, GOMF_GTPASE_BINDING, GGGTGGRR_PAX4_03, GNF2_ANK1, PATIL_LIVER_CANCER

GO Biological Process (6): protein export from nucleus (GO:0006611), intracellular protein transport (GO:0006886), nucleocytoplasmic transport (GO:0006913), protein transport (GO:0015031), nuclear export (GO:0051168), nuclear transport (GO:0051169)

GO Molecular Function (3): nuclear export signal receptor activity (GO:0005049), small GTPase binding (GO:0031267), protein binding (GO:0005515)

GO Cellular Component (3): nucleus (GO:0005634), nuclear pore (GO:0005643), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
nuclear export	2
intracellular protein localization	2
intracellular transport	2
intracellular protein transport	1
protein transport	1
nuclear transport	1
transport	1
establishment of protein localization	1
nucleocytoplasmic transport	1
intercellular transport	1
nucleocytoplasmic carrier activity	1
GTPase binding	1
binding	1
intracellular membrane-bounded organelle	1
nuclear envelope	1
nuclear protein-containing complex	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1330 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
XPO7	XPO6	Q96QU8	805
XPO7	CSE1L	P55060	759
XPO7	XPOT	O43592	744
XPO7	XPO1	O14980	674
XPO7	IPO13	O94829	674
XPO7	IPO5	O00410	655
XPO7	IPO4	Q8TEX9	622
XPO7	TNPO2	O14787	621
XPO7	TNPO1	Q92973	615
XPO7	XPO5	Q9HAV4	608
XPO7	IPO11	Q9UI26	565
XPO7	XPO4	Q9C0E2	564
XPO7	IPO8	O15397	538
XPO7	IPO7	O95373	520
XPO7	RANBP3	Q9H6Z4	519

IntAct

210 interactions, top by confidence:

A	B	Type	Score
HRAS	RAF1	psi-mi:“MI:0914”(association)	0.980
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
SCN2B	EXOC5	psi-mi:“MI:0914”(association)	0.640
VSIG1	TTI1	psi-mi:“MI:0914”(association)	0.640
XPO7	USO1	psi-mi:“MI:0915”(physical association)	0.560
USO1	XPO7	psi-mi:“MI:0915”(physical association)	0.560
CUTC	XPO7	psi-mi:“MI:0915”(physical association)	0.560
RAN	XPO7	psi-mi:“MI:0915”(physical association)	0.560
	XPO7	psi-mi:“MI:0915”(physical association)	0.560
HTR2C	KLRG2	psi-mi:“MI:0914”(association)	0.530
MAS1	POTEF	psi-mi:“MI:0914”(association)	0.530
TMEM108	TCAF2	psi-mi:“MI:0914”(association)	0.530
APLNR	METTL15	psi-mi:“MI:0914”(association)	0.530
VASN	AP3B1	psi-mi:“MI:0914”(association)	0.530
FZD10	NRP1	psi-mi:“MI:0914”(association)	0.530
NT5E	SCAMP1	psi-mi:“MI:0914”(association)	0.530
VSIG2	TTI1	psi-mi:“MI:0914”(association)	0.530
CD274	TTI1	psi-mi:“MI:0914”(association)	0.530
SLC39A9	B4GALT5	psi-mi:“MI:0914”(association)	0.530
CD70	METTL15	psi-mi:“MI:0914”(association)	0.530
PDCD1	RTL8C	psi-mi:“MI:0914”(association)	0.530
VSIG1	TNPO2	psi-mi:“MI:0914”(association)	0.530

BioGRID (1164): XPO7 (Two-hybrid), XPO7 (Affinity Capture-RNA), XPO7 (Affinity Capture-RNA), XPO7 (Affinity Capture-RNA), XPO7 (Affinity Capture-MS), XPO7 (Affinity Capture-MS), XPO7 (Affinity Capture-MS), XPO7 (Affinity Capture-MS), XPO7 (Affinity Capture-MS), XPO7 (Affinity Capture-MS), XPO7 (Affinity Capture-MS), XPO7 (Affinity Capture-MS), XPO7 (Affinity Capture-MS), XPO7 (Affinity Capture-MS), DSCR3 (Co-fractionation)

ESM2 similar proteins: A1CAU2, A1DEK2, A2QMS5, A5D785, A5WW24, A6RVT8, A7EPT5, B0Y4D6, B2AXG6, B8ARW2, B9FDR3, O13671, O13864, O14089, O18388, O43747, O59809, P14068, P30822, P33307, P55060, Q06142, Q0CIL3, Q1DY99, Q2H6R9, Q2U3V3, Q4WUV9, Q54EV7, Q569Z2, Q5R9G4, Q5R9J2, Q5ZLT0, Q6GMY9, Q704U0, Q7PC79, Q7RWV9, Q7SZC2, Q8AY73, Q8H0U4, Q8K2V6

Diamond homologs: Q54DN3, Q569Z2, Q5R9G4, Q5ZLT0, Q704U0, Q99NF8, Q9EPK7, Q9GQN0, Q9H2T7, Q9UIA9

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

95 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	48
Likely benign	1
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

4040 predictions. Top by Δscore:

Variant	Effect	Δscore
8:21966999:G:GT	donor_gain	1.0000
8:21966999:G:T	donor_gain	1.0000
8:21966999:GAAGT:G	donor_gain	1.0000
8:21967002:GT:G	donor_gain	1.0000
8:21967004:GTGC:G	donor_gain	1.0000
8:21967006:GC:G	donor_gain	1.0000
8:21967008:G:GG	donor_gain	1.0000
8:21967030:GA:G	donor_gain	1.0000
8:21969480:C:G	acceptor_gain	1.0000
8:21969481:A:AG	acceptor_gain	1.0000
8:21969482:G:GG	acceptor_gain	1.0000
8:21969482:GTC:G	acceptor_gain	1.0000
8:21969482:GTCCT:G	acceptor_gain	1.0000
8:21969572:TATTC:T	donor_gain	1.0000
8:21969577:G:GG	donor_gain	1.0000
8:21970142:A:AG	acceptor_gain	1.0000
8:21970142:AG:A	acceptor_gain	1.0000
8:21970142:AGG:A	acceptor_gain	1.0000
8:21970143:G:GG	acceptor_gain	1.0000
8:21970143:GG:G	acceptor_gain	1.0000
8:21970143:GGG:G	acceptor_gain	1.0000
8:21970143:GGGAA:G	acceptor_gain	1.0000
8:21970307:ACAG:A	donor_loss	1.0000
8:21970308:CAG:C	donor_loss	1.0000
8:21970310:GG:G	donor_loss	1.0000
8:21970311:G:GC	donor_loss	1.0000
8:21974663:T:A	acceptor_gain	1.0000
8:21974668:A:AG	acceptor_gain	1.0000
8:21974669:G:GG	acceptor_gain	1.0000
8:21974669:GGC:G	acceptor_gain	1.0000

AlphaMissense

7158 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:21966987:T:C	L50P	1.000
8:21966990:T:A	L51H	1.000
8:21966990:T:C	L51P	1.000
8:21969505:C:A	A63E	1.000
8:21969508:C:A	A64D	1.000
8:21969517:T:C	L67P	1.000
8:21969565:G:C	R83P	1.000
8:21970144:G:C	R87P	1.000
8:21970207:T:C	L108P	1.000
8:21970242:T:A	W120R	1.000
8:21970242:T:C	W120R	1.000
8:21971900:G:C	G151R	1.000
8:21971901:G:A	G151D	1.000
8:21971922:T:C	L158P	1.000
8:21974701:G:C	R175T	1.000
8:21974702:A:C	R175S	1.000
8:21974702:A:T	R175S	1.000
8:21974721:C:A	R182S	1.000
8:21974722:G:C	R182P	1.000
8:21976423:T:C	L222P	1.000
8:21976447:A:T	D230V	1.000
8:21976449:T:C	F231L	1.000
8:21976451:C:A	F231L	1.000
8:21976451:C:G	F231L	1.000
8:21976455:G:C	G233R	1.000
8:21976456:G:A	G233D	1.000
8:21976504:C:A	P249H	1.000
8:21976504:C:G	P249R	1.000
8:21976512:T:A	W252R	1.000
8:21976512:T:C	W252R	1.000

dbSNP variants (sampled 300 via entrez): RS1000007426 (8:21919730 G>A,C,T), RS1000049065 (8:21955769 T>C), RS1000059439 (8:21988954 C>G,T), RS1000143429 (8:22002518 C>G), RS1000235806 (8:21918374 G>A), RS1000244590 (8:21995090 A>G), RS1000266911 (8:21918658 A>C), RS1000273526 (8:21984625 T>G), RS1000274333 (8:21954969 A>G), RS1000319347 (8:21928637 C>T), RS1000427354 (8:21960947 C>A,T), RS1000482308 (8:21972367 G>A,T), RS1000482694 (8:21924171 C>A), RS1000510062 (8:21966664 C>T), RS1000516890 (8:21949173 T>A)

Disease associations

OMIM: gene MIM:606140 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
prostate cancer	Limited	Autosomal dominant

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

36 associations (top):

Study	Trait	p-value
GCST000585_8	Mean corpuscular volume	3.000000e-08
GCST004006_9	Mean corpuscular hemoglobin	5.000000e-07
GCST004601_104	Red blood cell count	6.000000e-15
GCST004602_62	Mean corpuscular volume	4.000000e-33
GCST004630_266	Mean corpuscular hemoglobin	7.000000e-33
GCST004749_22	Lung cancer in ever smokers	3.000000e-06
GCST005993_40	Mean corpuscular hemoglobin	3.000000e-21
GCST006011_72	Mean corpuscular volume	3.000000e-24
GCST006061_184	Atrial fibrillation	4.000000e-15
GCST006061_44	Atrial fibrillation	4.000000e-13
GCST006414_130	Atrial fibrillation	4.000000e-10
GCST008675_2	Maximum habitual alcohol consumption	2.000000e-08
GCST008675_8	Maximum habitual alcohol consumption	4.000000e-08
GCST009391_52	Metabolite levels	3.000000e-06
GCST010002_271	Refractive error	2.000000e-17
GCST010320_65	PR interval	6.000000e-07
GCST010321_37	PR interval	1.000000e-08
GCST010796_4381	Electrocardiogram morphology (amplitude at temporal datapoints)	8.000000e-11
GCST010796_4382	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-08
GCST010796_4383	Electrocardiogram morphology (amplitude at temporal datapoints)	3.000000e-08
GCST010796_4384	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-09
GCST010796_4385	Electrocardiogram morphology (amplitude at temporal datapoints)	9.000000e-09
GCST010796_4386	Electrocardiogram morphology (amplitude at temporal datapoints)	3.000000e-09
GCST010796_4387	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-10
GCST010796_4388	Electrocardiogram morphology (amplitude at temporal datapoints)	5.000000e-10
GCST010796_4389	Electrocardiogram morphology (amplitude at temporal datapoints)	3.000000e-09
GCST010796_4390	Electrocardiogram morphology (amplitude at temporal datapoints)	3.000000e-09
GCST010796_4391	Electrocardiogram morphology (amplitude at temporal datapoints)	3.000000e-08
GCST90002390_175	Mean corpuscular hemoglobin	2.000000e-70
GCST90002392_344	Mean corpuscular volume	8.000000e-93

EFO canonical traits (7, from GWAS)

EFO ID	Trait name
EFO:0004527	mean corpuscular hemoglobin
EFO:0004305	erythrocyte count
EFO:0010474	cystathionine measurement
EFO:0004462	PR interval
EFO:0004327	electrocardiography
EFO:0010701	mean reticulocyte volume
EFO:0007984	platelet component distribution width

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6067212 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

4 potent at pChembl≥5 of 4 total, top 4 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.76	Kd	17.28	nM	CHEMBL5653589
7.76	ED50	17.28	nM	CHEMBL5653589
7.29	Kd	51.68	nM	CHEMBL3752910
7.29	ED50	51.68	nM	CHEMBL3752910

PubChem BioAssay actives

2 with measured affinity, of 4 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149789: Binding affinity to human XPO7 incubated for 45 mins by Kinobead based pull down assay	kd	0.0173	uM
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149789: Binding affinity to human XPO7 incubated for 45 mins by Kinobead based pull down assay	kd	0.0517	uM

CTD chemical–gene interactions

35 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression, decreases methylation	4
methacrylaldehyde	affects cotreatment, increases oxidation, increases abundance	2
Acrolein	increases oxidation, increases abundance, affects cotreatment	2
Calcitriol	decreases expression	2
Ozone	affects cotreatment, increases oxidation, increases abundance	2
aristolochic acid I	decreases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
trichostatin A	increases expression	1
sodium arsenite	decreases expression	1
CGP 52608	affects binding, increases reaction	1
entinostat	decreases expression	1
nutlin 3	affects cotreatment, increases secretion	1
bisphenol S	increases expression	1
3-(2-hydroxy-4-(2-methylnonan-2-yl)phenyl)cyclohexan-1-ol	increases expression	1
bisphenol AF	increases expression	1
Irinotecan	decreases expression	1
Acetaminophen	decreases expression	1
Air Pollutants	affects cotreatment, increases abundance, increases oxidation	1
Benzo(a)pyrene	affects methylation	1
Benztropine	affects cotreatment, increases expression	1
Cadmium	decreases expression, increases abundance	1
Cannabidiol	decreases expression	1
Coumestrol	increases expression	1
Cuprizone	affects cotreatment, increases expression	1
Dactinomycin	affects cotreatment, increases secretion	1
Ivermectin	decreases expression	1
Phthalic Acids	increases methylation	1
Ribonucleotides	affects binding	1
Rotenone	increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5652831	Binding	Binding affinity to human XPO7 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer